In a systematic review of PD-1 inhibitor-related sclerosing cholangitis cases, Onoyama et al. evaluated the clinical and pathological features of 31 cases, including three cases of gastric cancer and 10 patients treated with pembrolizumab [14]. The gene discussed is PDCD1; the disease is sclerosing cholangitis.